Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study.
The Helsinki Heart Study demonstrated a 34% (p less than 0.02) reduction in the incidence of cardiac end points (myocardial infarction and cardiac death) with the use of gemfibrozil compared with the use of a placebo in dyslipidemic middle-aged men. The major effect was confined to nonfatal myocardial infarctions. In this study we analyzed the effect of gemfibrozil therapy on the incidences of Q wave and non-Q wave infarctions, since the long-term prognoses of these two types of myocardial infarction may be different. The analyses indicated a 45% reduction (P less than 0.02, log-rank test) in the cumulative incidence of Q wave infarctions in the gemfibrozil group without a statistically significant effect on either the rate of non-Q wave infarctions or of coronary deaths. The reduction in the incidence of Q wave infarctions became evident during the second half of the 5-year study period.
Mänttäri
M
M
First Department of Medicine, Helsinki University Central Hospital, Finland.
Romo
M
M
Manninen
V
V
Koskinen
P
P
Huttunen
J K
JK
Heinonen
O P
OP
Frick
M H
MH
D003402:Creatine Kinase / Q000378:metabolism; D004311:Double-Blind Method; D004562:Electrocardiography; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D015996:Survival Rate
D003402:Creatine Kinase; D015248:Gemfibrozil